This review highlights recent insights into metabolic changes in hypertrophic cardiomyopathies and discusses potential therapies targeting these metabolic disturbances.
Answers are grounded in this paper and cite their sources.
May inform metabolic-targeted approaches in genetic HCM; leaves open confirmation in clinical trials.
Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the cardiovascular research spotlight issue on metabolic cardiomyopathies).1 In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Herein, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy and discuss several therapies, which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Velden et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: